Medicine

The Affects of ENV-101 on IPF

December 27, 2024 - By 

John Hood, CEO, Endeavor BioMedicines discusses the key differences between ENV-101 and currently approved IPF treatments.

Related Posts

FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk

February 19, 2025

Navigating Distrust: Pharma in the Age of Social Media

February 19, 2025

Pharmaceutical Executive: February 2025 Issue (PDF)

February 18, 2025

Leave a Reply

Your email address will not be published. Required fields are marked *